Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98

Clin Microbiol Infect. 2001 Oct;7(10):553-61. doi: 10.1046/j.1198-743x.2001.00322.x.

Abstract

Objectives: To assess trends in quinolone susceptibility of Enterobacteriaceae isolated in a large university hospital.

Methods: Between 1992 and 1998, bacterial isolates were collected each year during a 3-month period to evaluate annual changes in susceptibility. In addition, the activities of fluoroquinolones (pefloxacin, norfloxacin, ofloxacin, ciprofloxacin) against nalidixic acid-resistant strains were determined by disk diffusion and MIC methodologies during the first and last year of the study.

Results: The susceptibility of Enterobacteriaceae to nalidixic acid was unchanged between 1992 and 1998 (86% versus 85%). However, at the species level, the susceptibility rates to nalidixic acid decreased for Escherichia coli from 92% to 89%, and for Enterobacter cloacae from 87% to 82%. In contrast, there was a 10% increase in the nalidixic acid susceptibility rates for Klebsiella pneumoniae (74% versus 83%), which was thought to be due to the control of the spread of epidemic extended-spectrum beta-lactamase (ESBL)-producing strains. The overall susceptibility of the Enterobacteriaceae to the fluoroquinolones remained high during the study period, greater than 90% in the case of ciprofloxacin. However, nalidixic acid-resistant Escherichia coli showed decreased susceptibility to ciprofloxacin between 1992 and 1998, as reflected by a decrease in median zone diameter (26 mm to 19 mm), an increase in MIC(50) (0.25 mg/L to 1 mg/L) and a shift in MIC distribution (unimodal in 1992 to bimodal in 1998). This has resulted in the reduced susceptibility of Escherichia coli to fluoroquinolones between 1992 and 1998 (pefloxacin, 95-90%; ciprofloxacin, 99-95%).

Conclusions: The susceptibility of Escherichia coli to quinolones has decreased, and the level of susceptibility of the resistant strains has increased over the 7-year study period.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Anti-Infective Agents / therapeutic use
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Bacterial
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / growth & development
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / microbiology*
  • France
  • Hospitals, University
  • Humans
  • Microbial Sensitivity Tests
  • Nalidixic Acid / pharmacology

Substances

  • Anti-Infective Agents
  • Nalidixic Acid
  • Ciprofloxacin